{"id":22973,"date":"2022-12-23T21:45:23","date_gmt":"2022-12-23T21:45:23","guid":{"rendered":"https:\/\/dailytalks.org\/?p=22973"},"modified":"2022-12-23T21:45:23","modified_gmt":"2022-12-23T21:45:23","slug":"finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=22973","title":{"rendered":"Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes"},"content":{"rendered":"<p>Berlin, December 16, 2022 \u2013 Bayer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending a label extension for Kerendia&#x2122; (finerenone, 10 mg or 20 mg) to include results on cardiovascular outcomes from the Phase III FIGARO-DKD study&#8230;<br \/><a href=\"https:\/\/www.bayer.com\/media\/en-us\/finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Berlin, December 16, 2022 \u2013 Bayer announced today that the Committee for Medicinal Products for<\/p>\n","protected":false},"author":1,"featured_media":22974,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-22973","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes.jpg",1200,630,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-300x158.jpg",300,158,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-768x403.jpg",640,336,true],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-1024x538.jpg",640,336,true],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes.jpg",1200,630,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes.jpg",1200,630,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-1024x538.jpg",1024,538,true],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-825x575.jpg",825,575,true],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/22973-finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=16\" rel=\"category\">Europe<\/a>","tag_info":"Europe","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/22973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22973"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/22973\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/22974"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}